Dan Ory

Dan Ory comes to Arbor from Casma Therapeutics, a Third Rock Ventures start up, where he served as Senior VP of Translational Medicine and later as Chief Medical Officer. While at Casma, Dan oversaw programs in muscular dystrophy and rare oncology indications. Prior to joining Casma, Dan was on faculty at Washington University in St. Louis, where he was an endowed, tenured professor of medicine and cell biology. During his more than two decades at the University, Dan’s research centered on cholesterol homeostasis and its role in cardiovascular disorders and Niemann-Pick Type C (NPC) disease, a rare, neurodegenerative disorder. He led multiple clinical trials in NPC disease and was scientific co-founder of Vtesse Therapeutics, which developed the Phase 2b/3 adrabetadex trial for NPC patients. Dan has authored over 160 peer-reviewed publications and holds numerous patents. He is a valued consultant in the scientific community and has served on scientific advisory boards of biotech companies – Kisbee Therapeutics and Stride Bio – and disease foundations – Ara Parseghian Medical Research Foundation, and Salla Treatment and Research Foundation, among others. As a champion of rare disease research, Dan has been honored many times for his work, including the Global Genes RARE Champion of Hope Award. Dan has an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women’s Hospital, his fellowship in Cardiology at MGH, and his postdoctoral studies at the Whitehead Institute at MIT. Outside of Arbor, Dan enjoys traveling with his wife and family, running, tennis, and spending time at the beach.